SCA
VRTX icon

SAC Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

SAC Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-114,954
Closed -$8.13M – 1004
2014
Q1 		$8.13M Buy
+114,954
New +$9.1M 0.04% 452
2013
Q4 		– Sell
-94,900
Closed -$7.2M – 1990
2013
Q3 		$7.2M Sell
94,900
-457,026
-83% -$36.4M 0.04% 453
2013
Q2 		$44.1M Buy
+551,926
New +$40.6M 0.24% 117

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

SAC Capital Advisors's VRTX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2014, closing a stake of 114,954 shares — an estimated $8.13M sold.

SAC Capital Advisors first reported a position in VRTX in Q2 2013 and held it in 3 quarters. The position peaked at $44.1M in Q2 2013. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 114,954 Vertex Pharmaceuticals shares in Q2 2014, an estimated $8.13M.
  • SAC Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Vertex Pharmaceuticals position peaked at $44.1M in Q2 2013.
  • 411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.